Compare CION & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CION | NPCE |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.0M | 485.6M |
| IPO Year | 2011 | 2021 |
| Metric | CION | NPCE |
|---|---|---|
| Price | $6.71 | $13.01 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $18.33 |
| AVG Volume (30 Days) | ★ 707.1K | 196.8K |
| Earning Date | 03-12-2026 | 03-03-2026 |
| Dividend Yield | ★ 17.75% | N/A |
| EPS Growth | N/A | ★ 29.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $99,986,000.00 |
| Revenue This Year | N/A | $0.90 |
| Revenue Next Year | N/A | $24.46 |
| P/E Ratio | $17.55 | ★ N/A |
| Revenue Growth | N/A | ★ 25.13 |
| 52 Week Low | $6.50 | $7.56 |
| 52 Week High | $11.07 | $18.97 |
| Indicator | CION | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 19.83 | 32.96 |
| Support Level | N/A | $12.47 |
| Resistance Level | $10.30 | $13.81 |
| Average True Range (ATR) | 0.24 | 0.85 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 11.22 | 14.56 |
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.